Semaglutide: what has been tested in trials, and what has not
| Product | Tested in a trial? | Average weight loss | FDA review |
|---|---|---|---|
| Wegovy shot (semaglutide 2.4 mg) | Yes: STEP 1, 68 weeks | 14.9% vs 2.4% on placebo; 66.1% lost at least 10% | FDA-approved for weight loss |
| Wegovy pill (oral semaglutide 25 mg) | Yes: OASIS 4, 64 weeks | 13.6% vs 2.4% on placebo | FDA-approved for weight loss |
| Compounded semaglutide shot | No | No trial result exists | Not FDA-approved; not reviewed for safety, effectiveness or quality before it is sold |
| Compounded semaglutide tablet or drops | No | No trial result exists; how much the body absorbs is not established | Not FDA-approved; not reviewed before it is sold |
Trial results from the Wegovy prescribing information (STEP 1 and OASIS 4), as listed in our trial results table. FDA wording from its page on concerns with unapproved GLP-1 drugs used for weight loss.
Why no trial number exists for compounded semaglutide
A trial tests one finished product. STEP 1 tested Novo Nordisk's semaglutide, which the FDA then approved as Wegovy. A compounded vial is prepared by a pharmacy for one prescription and never goes through that process: compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are sold.
That is not evidence that compounded semaglutide fails. It means the trial result belongs to the brand, and a compounded vial can match it only if it delivers the same ingredient at the same dose.
What decides whether your compounded semaglutide works
- The ingredient. The FDA warns that semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drugs. Your vial label should name semaglutide.
- The strength. Vials differ in mg per mL, so the same number of units can be a different dose. Check the label each time a vial arrives.
- The dose you reach. On the Wegovy label the dose rises every 4 weeks, through 0.25, 0.5, 1 and 1.7 mg, to 2.4 mg from week 17. The 14.9% average was measured on 2.4 mg at week 68, not in the first months.
- Staying on it. In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping.
If it seems not to be working
Weight loss in the first weeks is often small, because the starting doses are low on purpose. If you have been on a steady dose for a while with little change, ask the clinician three things: whether your dose has reached the range the trials used, what strength your vial is and how many units your dose is, and whether another medicine fits better. In the one head-to-head trial, SURMOUNT-5, tirzepatide led to more weight loss than semaglutide.
The lowest compounded semaglutide prices among the programs we compare on Nov 12, 2026: $59 a month at SnagRx, month to month (pre-Black Friday sale price, was $299, locked in; the page counts down to a price increase); $89 a month on Lttl's 12-month plan; $96 a month on yourEra's 12-month plan ($1,152 billed upfront).







